Observation on Reflux Esophagitis of Middle Deficiency and Qi Rebellion Treated with Weikang Ⅰ Formula
NI Xiaoyan
AN Zhenxiang
Abstract：Objective:To observe the clinical efficacy of Weikang Ⅰ formula combined rabeprazole sodium enteric-coated capsule on reflux esophagitis(RE) of middle deficiency and qi rebellion type. Method:Sixty patients with RE were randomly divided into the control group and the treatment group, 30 cases in each group by a random number table. Patients in both two groups were given rabeprazole sodium enteric-coated capsule 20 mg in the morning and evening, and patients in the treatment group was also given Weikang Ⅰformula, 1 dose Ya day. In the two groups, the treatment lasted for 8 weeks and the clinical efficacy was observed. Results:The clinical effect of syndromes and the effect on inflammation under gastroscopy in the treatment group were better than those in the control group, with statistical difference(P＜0.05). The treatment group was lower than the control group on the traditional Chinese medicine symptom score, GerdQ score, with significant difference(P＜0.01). At 6-month follow-up, the recurrence rate in the treatment group was 21.4％ and was significantly lower than that in the control group 52.4％(P＜0.05). Conclusion:Weikang Ⅰformula combined with rabeprazole sodium enteric-coated capsule showed better curative effect for RE. It could alleviate the clinical symptom and reduce the recurrence rate.
Keywords：reflux esophagitisWeikang Ⅰ formulacombined treatmentrabeprazole sodium enteric-coated capsule
Publication Date：2018-01-01
Online Publishing Date：2026-05-22(First online date of this platform, not the publication date of the document)
Pages：3( 378-380 )